PharmaPoint: Hepatitis C Virus (HCV) Therapeutics – Global Drug Forecast and Market Analysis to 2025

The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug.

During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment arsenal has rapidly expanded from only one unsatisfactory option-peginterferon plus ribavirin-to a collection of combination and fixed-dose combination regimens that can cure most patients in as little as 8?12 weeks, many without the use of interferon and/or ribavirin. Currently, these interferon-free and interferon-sparing DAA regimens dominate the treatment landscape as they combine a very high cure rate with improved tolerability and simplified dosing.

Scope

Overview of hepatitis C infections, including epidemiology, etiology, pathophysiology, regional genotype distribution, as well current routine treatment recommendations of all 9MM covered.

Topline hepatitis C market revenue from 2015–2025. Recent acquisitions, approvals and governmental recommendations and restrictions are included in the forecast model.

Key topics covered include dynamics in the number of prevalent cases during the forecast, market characterization, unmet needs, and company strategies.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

Analysis of the current and future market competition in the global hepatitis C marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the hepatitis C marketplace.

What will be the effect of recent and upcoming approval of pan-genotypic DAA regimens?

How will patient populations develop with changing treatment rates and high cure rates?

What research and development (R&D) strategies will companies leverage to compete in the future hepatitis C marketplace?

Which patient population(s) are most likely to be targeted by upcoming pan-genotypic DAA treatment algorithms?

Companies mentioned

AbbVie

Bristol-Myers Squibb

Gilead Sciences

Janssen / Johnson & Johnson

Merck

Roche

AbbVie

Bristol-Myers Squibb

Gilead Sciences

Janssen / Johnson & Johnson

Merck

Roche

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Symptoms

3.3 Prognosis and Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.3.1 Diagnosed Incidence and Total Prevalence

4.3.2 Genotype

4.4 Forecast Methodology

4.4.1 Sources Used Tables

4.4.2 Forecast Assumptions and Methods

4.4.3 Sources Not Used

4.5 Epidemiological Forecast of HCV (2015–2025)

4.5.1 Total Prevalent Cases

4.5.2 Diagnosed Prevalent Cases

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis Overview

5.1.1 Initial Diagnosis and Referral

5.1.2 Patient Assessment

5.1.3 Viral Assessment

5.2 Treatment Guildines

5.3 US

5.3.1 Diagnosis

5.3.2 Treatment Guidelines

5.3.3 Clinical Practice and Coverage

5.4 5EU

5.4.1 Diagnosis Overview

5.4.2 Treatment Guidelines Overview

5.5 France

5.5.1 Diagnosis

5.5.2 Clinical Practice

5.6 Germany

5.6.1 Diagnosis

5.6.2 Clinical Practice

5.7 Italy

5.7.1 Diagnosis

5.7.2 Clinical Practice

5.8 Spain

5.8.1 Diagnosis

5.8.2 Clinical Practice

5.9 UK

5.9.1 Diagnosis

5.9.2 Clinical Practice

5.10 Japan

5.10.1 Diagnosis

5.10.2 Clinical Practice

5.11 Brazil

5.11.1 Diagnosis

5.11.2 Clinical Practice

5.12 China

5.12.1 Diagnosis

5.12.2 Clinical Practice

6 Competitive Assessment

6.1 Overview

6.2 Strategic Competitor Assessment

6.3 Major Brands – Fixed-Dose Combination Direct-Acting Antivirals

6.3.1 Harvoni (Ledipasvir/Sofosbuvir)

6.3.2 Viekira Pak (Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir) and Technivie (Ombitasvir/Paritaprevir/Ritonavir)

6.3.3 Zepatier (Elbasvir/Grazoprevir)

6.3.4 Epclusa (Sofosbuvir/Velpatasvir)

6.4 Major Brands – Single Component Direct-Acting Antivirals

6.4.1 Sovaldi (Sofosbuvir)

6.4.2 Daklinza (Daclatasvir)

6.4.3 Olysio (Simeprevir)

6.5 Major Brands – Peginterferon and Ribavirin

6.5.1 Pegasys (Peginterferon alfa-2a) and PegIntron (Peginterferon alfa-2b)

6.5.2 Copegus, Rebetol, and Generic Ribavirin

6.6 Other Branded Direct-Acting Antivirals

6.6.1 Incivek (Telaprevir) and Victrelis (Boceprevir)

6.6.2 Sunvepra (Asunaprevir)

6.6.3 Exviera (Dasabuvir)

6.6.4 Vanihep (Vaniprevir)

7 Unmet Needs and Opportunity Analysis

7.1 Overview

7.2 Reducing the Overall Cost Burden of Direct-Acting Antiviral Treatment Algorithms

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Increasing Awareness of Hepatitis C Treatment Opportunities

7.3.1 Adjusting the Approaches Physicians Take with Hepatitis C

7.3.2 Awareness in the General Population

7.4 Expanding Treatment Access

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Improving Diagnosis Rates in Patients with Chronic Hepatitis C Infection

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Reducing Frequency and Severity of Adverse Events in All Patient Groups

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Enhanced Cure Rates in Difficult-to-Treat Patients

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

7.8 Clinical Evalulation of Direct-Acting Antiviral Efficacy in Pediatric Patients

7.8.1 Unmet Need

7.8.2 Gap Analysis

7.8.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.2 Clinical Trial Mapping

8.2.1 Clinical Trials by Status and Phase

8.3 Promising DAA Regimens in Clinical Development

8.3.1 Sofosbuvir/Velpatasvir/Voxilaprevir

8.3.2 Glecaprevir/pibrentasvir

8.3.3 Asunaprevir/Beclabuvir/Daclatasvir

8.3.4 MK-3682A and MK-3682B

8.3.5 Odalasvir-Based Regimens

8.4 Other Products in Clinical Development

8.4.1 Investigational Therapies with Established MOAs

8.4.2 Investigational Therapies with Novel MOAs

8.4.3 Clinical Development Outside 9MM

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Gilead Sciences

9.3.2 AbbVie

9.3.3 Merck

9.3.4 Janssen

9.3.5 Bristol-Myers Squibb

9.3.6 Roche

9.4 Additional Companies with Promising Drugs

9.4.1 Regulus Therapeutics

9.4.2 Presidio Pharmaceuticals

9.4.3 Trek Therapeutics

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers – Global Issues

10.2 US

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5EU

10.3.1 5EU

10.3.2 France

10.3.3 Germany

10.3.4 Italy

10.3.5 Spain

10.3.6 UK

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 Brazil

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

10.6 China

10.6.1 Forecast

10.6.2 Key Events

10.6.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Patient Populations

11.4.2 Drugs Included in Each Therapeutic Class

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Individual Drug Assumptions

11.4.6 Generic Erosion

11.4.7 Pricing of Pipeline Agents

11.5 Primary Research – KOLs and Payers Interviewed for this Report

11.5.1 KOLs

11.5.2 Payers

11.6 Primary Research – Prescriber Survey

11.7 About the Authors

11.7.1 Analysts

11.7.2 Therapy Area Director

11.7.3 Epidemiologists

11.7.4 Global Director of Therapy Analysis and Epidemiology

11.8 About GlobalData

11.9 Disclaimer

List of tables

Table 1: Modes of HCV Transmission

Table 2: Symptoms of Acute and Chronic HCV Infection

Table 3: Risk Factors and Comorbidities Associated with HCV Infection ...

Table 1: Modes of HCV Transmission

Table 2: Symptoms of Acute and Chronic HCV Infection

Table 3: Risk Factors and Comorbidities Associated with HCV Infection

Table 4: 9MM, Anti-HCV+ Total Prevalence from 1988–2015

Table 5: Hepatitis C Virus Genotype Description

Table 6: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases

Table 7: 9MM, Sources Used to Forecast HCV RNA+ Total Prevalent Cases

Table 8: 9MM, Sources Used to Forecast Anti-HCV+ Total Prevalent Cases by HCV Genotypes

Table 9: 9MM, Sources Used to Forecast HCV/HIV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases

Table 10: 9MM, Sources Used to Forecast HCV/HBV Co-Infection Cases Among Anti-HCV+ Total Prevalent Cases

Table 11: 9MM, Sources Used to Forecast Anti-HCV+ Diagnosed Prevalent Cases

Table 12: 9MM, Sources Used to Forecast HCV RNA+ Diagnosed Prevalent Cases

Table 13: 9MM, Sources Used for Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status

Table 14: 9MM, Sources Not Used in Epidemiological Forecast for Anti-HCV+ Total Prevalent Cases

Table 15: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 16. 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015

Table 17: 9MM, Anti-HCV+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 18: 9MM, Anti-HCV+ Total Prevalent Cases, by HCV Genotype, All Ages, N (Row %), Both Sexes, 2015

Table 19: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 20. 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N (Row %), 2015

Table 21: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 22: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 23: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015

Table 24: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 25: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Table 26: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N (Row %), 2015

Table 27: 9MM, HCV RNA+ Diagnosed Prevalent Cases, by Sex, All Ages, N (Row %), 2015

Table 28: HCV Genotypes Prevalent in the 9MM

Table 29: General Standard of Care by HCV Genotype in 2015

Table 30: Treatment Guidelines for Hepatitis C

Table 31: Country Profile – US

Table 32: Recommended Treatment Options for Treatment-Naïve Patients in the US, 2016

Table 33: Country Profile – 5EU

Table 34: Recommended Treatment Options for Treatment-naïve Patients in the 5EU, 2016

Table 35: Country Profile – Japan

Table 36: Country Profile – Brazil

Table 37: Country Profile – China

Table 38: Leading Treatments for Hepatitis C, 2016

Table 39: Harvoni – Clinical Trials Supporting Regulatory Approval

Table 40: Product Profile – Harvoni

Table 41: Key Clinical Trials of Gilead’s Harvoni

Table 42: Safety of Harvoni – Most Common AEs

Table 43: Harvoni SWOT Analysis, 2016

Table 44: Global Sales Forecasts ($m) for Harvoni, 2015–2025

Table 45: Viekira Pak and Technivie – Key Clinical Trials Supporting Regulatory Approval

Table 46: Product Profile – Viekira Pak and Technivie

Table 47: Efficacy of Viekira Pak and Technivie – SVR12, Key Phase III and Phase II Studies

Table 48: Safety of Viekira Pak and Technivie – Most Common AEs

Table 49: Viekira Pak and Technivie SWOT Analysis, 2016

Table 50: Global Sales Forecast ($m) for Viekira Pak, 2015–2025

Table 51: Zepatier – Key Clinical Trials Supporting Regulatory Approval

Table 52: Product Profile – Zepatier

Table 53: Efficacy of Zepatier – SVR12, Key Phase III and Phase II Clinical Trials

Table 54: Treatment-Emergent Amino Acid Substitutions Among Virologic Failures of Zepatier

Table 55: Safety of Zepatier – Most Common AEs

Table 56: Zepatier SWOT Analysis, 2016

Table 57: Global Sales Forecasts ($m) for Zepatier, 2015–2025

Table 58: Key Clinical Trials of Gilead’s Epclusa

Table 59: Product Profile – Epclusa

Table 60: Efficacy of Epclusa – SVR12, Key Phase III Trials

Table 61: Safety of Epclusa – Most Common AEs

Table 62: Epclusa SWOT Analysis, 2016

Table 63: Global Sales Forecasts ($m) for Epclusa, 2015–2025

Table 64: Sovaldi – Clinical Trials Supporting Regulatory Approval

Table 65: Product Profile – Sovaldi

Table 66: Efficacy of Sovaldi – SVR12, Key Phase III Trials

Table 67: Safety of Sovaldi – Most Common AEs

Table 68: Sovaldi SWOT Analysis, 2016

Table 69: Global Sales Forecast ($m) for Sovaldi, 2015–2025

Table 70: Daklinza – Key Clinical Trials Supporting Regulatory Approval

Table 71: Product Profile – Daklinza

Table 72: Efficacy of Daklinza – SVR12, Key Phase IIb and III Trials

Table 73: Safety of Daklinza – Most Common AEs

Table 74: Daklinza SWOT Analysis, 2016

Table 75: Global Sales Forecast ($m) for Daklinza, 2015–2025

Table 76: Olysio – Key Clinical Trials Supporting Regulatory Approval

Table 77: Product Profile – Olysio

Table 78: Efficacy of Olysio – SVR12, Key Phase III and Phase II Trials

Table 79: Safety of Olysio – Most Common AEs in Clinical Trials

Table 80: Olysio SWOT Analysis, 2016

Table 81: Global Sales Forecasts ($m) for Olysio, 2015–2025

Table 82: Product Profile – Pegasys

Table 83: Product Profile – PegIntron

Table 84: Efficacy of Pegasys with or without Ribavirin Compared with Interferon Alfa-2b

Table 85: Efficacy of PegIntron Compared With Interferon Alfa-2b

Table 86: Pegasys and PegIntron SWOT Analysis, 2016

Table 87: Global Sales Forecast ($m) for Pegasys, 2015–2025

Table 88: Global Sales Forecast ($m) for PegIntron, 2015–2025

Table 89: Ribavirin SWOT Analysis, 2016

Table 90: Global Sales Forecast ($m) for Copegus, 2015–2025

Table 91: Global Sales Forecast ($m) for Rebetol, 2015–2025

Table 92: Summary of Other Branded DAAs, 2016

Table 93: Unmet Needs and Opportunities in Chronic Hepatitis C

Table 94: Hepatitis C Virus Infection – Late-Stage Pipeline, 2016

Table 95: Key Clinical Trials of Gilead’s Sofosbuvir/Velpatasvir/Voxilaprevir Combination

Table 96: Product Profile – Sofosbuvir/Velpatasvir/Voxilaprevir

Table 97: Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Phase II Clinical Trials

Table 98: Sofosbuvir/Velpatasvir/Voxilaprevir SWOT Analysis, 2016

Table 99: Global Sales Forecast ($m) for Sofosbuvir/Velpatasvir/Voxilaprevir, 2015–2025

Table 100: Phase III Clinical Trials of AbbVie’s Glecaprevir/Pibrentasvir Combination

Table 101: Product Profile – Glecaprevir/Pibrentasvir

Table 102: Efficacy of Glecaprevir/Pibrentasvir in Phase II Trials

Table 103: Most Common AEs of Glecaprevir/Pibrentasvir in Phase II Trials

Table 104: Glecaprevir/Pibrentasvir SWOT Analysis, 2016

Table 105: Global Sales Forecast ($m) for Glecaprevir/Pibrentasvir, 2015–2025

Table 106: Phase III Clinical Trials of BMS’s Asunaprevir/Beclabuvir/Daclatasvir

Table 107: Product Profile – Asunaprevir/Beclabuvir/Daclatasvir

Table 108: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Phase III Clinical Trials

Table 109: Efficacy of Asunaprevir/Beclabuvir/Daclatasvir in Japanese Patients

Table 110: Asunaprevir/Beclabuvir/Daclatasvir SWOT Analysis, 2016

Table 111: Global Sales Forecast ($m) for Asunaprevir/Beclabuvir/Daclatasvir, 2015–2025

Table 112: On-Going Phase II Clinical Trials of MK-3682A and MK-3682B

Table 113: Product Profile – MK-3682A and MK-3682B

Table 114: Efficacy of MK-3682A and MK-3682B in Phase II Trials

Table 115: MK-3682A and MK-3682B SWOT Analysis, 2016

Table 116: Global Sales Forecasts ($m) for MK-3682A and MK-3682B, 2015–2025

Table 117: Phase II Clinical Trials involving Achillion and Janssen’s Odalasvir

Table 118: Product Profile – AL-335/odalasvir/simeprevir

Table 119: AL-335/Odalasvir/Simeprevir SWOT Analysis, 2016

Table 120: Global Sales Forecast ($m) for AL-335/Odalasvir/Simeprevir, 2015–2025

Table 121: Other Products in Clinical Development for HCV Infection, 2016

Table 122: Clinical Development outside 9MM, 2016

Table 123: Key Companies in the HCV Marketplace in the 9MM, 2016

Table 124: Gilead’s HCV Portfolio Assessment, 2016

Table 125: AbbVie’s HCV Portfolio Assessment, 2016

Table 126: Merck’s HCV Portfolio Assessment, 2016

Table 127: Janssen’s HCV Portfolio Assessment, 2016

Table 128: BMS’ HCV Portfolio Assessment, 2016

Table 129: Roche’s HCV Portfolio Assessment, 2016

Table 130: Regulus’ HCV Portfolio Assessment, 2016

Table 131: Presidio’s HCV Portfolio Assessment, 2016

Table 132: Trek Therapeutics’ HCV Portfolio Assessment, 2016

Table 133: Global (9MM) Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 134: 9MM Chronic Hepatitis C Market – Drivers and Barriers, 2015-2025

Table 135: US Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 136: Key Events Impacting Sales for Chronic Hepatitis C in the US, 2015–2025

Table 137: Chronic Hepatitis C Market – Drivers and Barriers in the US, 2015–2025

Table 138: 5EU Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 139: Key Events Impacting Sales for Chronic Hepatitis C in the 5EU, 2015–2025

Table 140: Chronic Hepatitis C Market – Drivers and Barriers in the 5EU, 2015–2025

Table 141: France Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 142: Key Events Impacting Sales for Chronic Hepatitis C in France, 2015–2025

Table 143: Chronic Hepatitis C Market – Drivers and Barriers in France, 2015–2025

Table 144: Germany Sales Forecasts ($m) for Hepatitis C, 2015–2025

Table 145: Key Events Impacting Sales for Chronic Hepatitis C in Germany, 2015–2025

Table 146: Chronic Hepatitis C Market – Drivers and Barriers in Germany, 2015–2025

Table 147: Italy Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 148: Key Events Impacting Sales for Chronic Hepatitis C in Italy, 2015–2025

Table 149: Chronic Hepatitis C Market – Drivers and Barriers in Italy, 2015–2025

Table 150: Spain Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 151: Key Events Impacting Sales for Chronic Hepatitis C in Spain, 2015–2025

Table 152: Chronic Hepatitis C Market – Drivers and Barriers in Spain, 2015–2025

Table 153: UK Sales Forecasts ($m) for Hepatitis C, 2015–2025

Table 154: Key Events Impacting Sales for Chronic Hepatitis C in the UK, 2015–2025

Table 155: Chronic Hepatitis C Market – Drivers and Barriers in the UK, 2015–2025

Table 156: Japan Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 157: Key Events Impacting Sales for Chronic Hepatitis C in Japan, 2015–2025

Table 158: Chronic Hepatitis C Market – Drivers and Barriers in Japan, 2015–2025

Table 159: Brazil Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 160: Key Events Impacting Sales for Chronic Hepatitis C in Brazil, 2015–2025

Table 161: Chronic Hepatitis C Market – Drivers and Barriers in Brazil, 2015–2025

Table 162: China Sales Forecast ($m) for Hepatitis C, 2015–2025

Table 163: Key Events Impacting Sales for Chronic Hepatitis C in China, 2015–2025

Table 164: Chronic Hepatitis C Market – Drivers and Barriers in China, 2015–2025

Table 165 Key Historical and Projected Launch Dates for Chronic Hepatitis C

Table 166 Key Historical and Projected Patent Expiry Dates for Chronic Hepatitis C

Table 167: High Prescribers Surveyed

List of figures

Figure 1: HCV Genome and Polyprotein Composition

Figure 2: HCV Lifecycle Overview

Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected ...

Figure 1: HCV Genome and Polyprotein Composition

Figure 2: HCV Lifecycle Overview

Figure 3: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 4: 9MM, Anti-HCV+ Total Prevalent Cases, by Age, Both Sexes, N, 2015

Figure 5: 9MM, Anti-HCV+ Total Prevalent Cases, All Ages, by Sex, N, 2015

Figure 6: 9MM, Age-Standardized Anti-HCV+ Total Prevalence, All Ages, by Sex, %, 2015

Figure 7: 9MM, HIV and HBV Co-Infections Among Anti-HCV+ Total Prevalent Cases, All Ages, Both Sexes, N, 2015

Figure 8: 9MM, HCV RNA+ Total Prevalent Cases, All Ages, Both Sexes, N, Selected Years, 2015–2025

Figure 9: 9MM, HCV RNA+ Total Prevalent Cases, by Age, Both Sexes, N, 2015

Figure 10: 9MM, HCV RNA+ Total Prevalent Cases, by Sex, N, 2015

Figure 11: 9MM, Age-Standardized HCV RNA+ Total Prevalence, All Ages, by Sex, %, 2015

Figure 12: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 13: 9MM, Age-Specific Anti-HCV+ Diagnosed Prevalent Cases, Both Sexes, N, 2015

Figure 14: 9MM, Anti-HCV+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015

Figure 15: 9MM, Age-Standardized Anti-HCV+ Diagnosed Prevalence, All Ages, by Sex, %, 2015

Figure 16: 9MM, Anti-HCV+ Diagnosed Prevalent Cases by Liver Cirrhosis Status, All Ages, Both Sexes, N, 2015

Figure 17: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, Both Sexes, N, Selected Years 2015–2025

Figure 18: 9MM, Age-Specific HCV RNA+ Diagnosed Prevalent Cases, Both Sexes, N, 2015

Figure 19: 9MM, HCV RNA+ Diagnosed Prevalent Cases, All Ages, by Sex, N, 2015

Figure 20: 9MM, Age-Standardized HCV RNA+ Diagnosed Prevalence, All Ages, by Sex, %, 2015

Figure 21: Hepatitis C – Clinical Trials by Status and Phase, 2016

Figure 22: HCV Infection Therapies – Phase II–III Pipeline, 2016

Figure 23: Competitive Assessment of Late-Stage Pipeline Agents for HCV Infection, 2015–2025

Figure 24: Clinical and Commercial Positioning of Sofosbuvir/Velpatasvir/Voxilaprevir

Figure 25: Clinical and Commercial Positioning of Glecaprevir/Pibrentasvir

Figure 26: Clinical and Commercial Positioning of Asunaprevir/Beclabuvir/Daclatasvir

Figure 27: Clinical and Commercial Positioning of MK-3682A and MK-3682B

Figure 28: Clinical and Commercial Positioning of Odalasvir-Based Regimens

Figure 29: Company Market Share in HCV, 2015 and 2025

Figure 30: Company Portfolio Gap Analysis in HCV, 2015–2025

Figure 31: Annual Global (9MM) Sales of DAAs, by Region, in 2015 and 2025

Figure 32: Annual Global (9MM) Sales of DAAs, by Brand, in 2015 and 2025

Figure 33: Annual Sales of DAAs in the US in 2015 and 2025

Figure 34: Annual Sales of DAAs in the 5EU in 2015 and 2025

Figure 35: Annual Sales of DAAs in France in 2015 and 2025

Figure 36: Annual Sales of DAAs in Germany in 2015 and 2025

Figure 37: Annual Sales of DAAs in Italy in 2015 and 2025

Figure 38: Annual Sales of DAAs in Spain in 2015 and 2025

Figure 39: Annual Sales of DAAs in the UK in 2015 and 2025

Figure 40: Annual Sales of DAAs in Japan in 2015 and 2025

Figure 41: Annual Sales of DAAs in Brazil in 2015 and 2025

Figure 42: Annual Sales of DAAs in China in 2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports